LMNL — Liminal BioSciences Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- $27.62m
- $14.21m
- CA$0.40m
Liminal BioSciences rises on plans to spin-off non-core assets
Brief: Liminal Biosciences Inc - Plans To Divest Its Remaining Non-Core Assets, To Further Extend Runway
Brief: Liminal Biosciences Announces Priorities For 2023
Brief: Liminal Biosciences Reports Third Quarter 2022 Financial Results
Brief: Liminal Biosciences Reports Third Quarter 2022 Financial Results
Brief: Liminal Biosciences Announces Listing Transfer To Nasdaq Capital Market
Brief: Liminal Biosciences Announces Termination Of Legacy CDMO Contract
Brief: Liminal Biosciences Reports Second Quarter 2022 Financial Results
Brief: Liminal BioSciences Announces Discontinuation Of Fezagepras Development
Brief: Liminal BioSciences Doses First Subject In Phase 1A Trial Of Fezagepras
Brief: Liminal BioSciences Reports First Quarter 2022 Results
Liminal BioSciences Inc reports results for the quarter ended in December - Earnings Summary
Brief: Liminal BioSciences Provides Update On Its Lead Drug Candidate Fezagepras
Brief: Liminal BioSciences Provides Update On Its Lead Drug Candidate Fezagepras
Brief: Liminal BioSciences Reports Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
Brief: Liminal BioSciences Reports Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Brief: Liminal Biosciences Repays Its Secured Debt Ending Its Creditor Relationship With Structured Alpha Lp
Brief: Ocugen Signs Letter Of Intent To Acquire Vaccine Manufacturing, R&D Hub In Ontario, Canada
Brief: Liminal Biosciences Announces Strategic Priorities For 2022